1. Home
  2. PERI vs AGEN Comparison

PERI vs AGEN Comparison

Compare PERI & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Perion Network Ltd.

PERI

Perion Network Ltd.

SELL

Current Price

$8.72

Market Cap

346.5M

Sector

Technology

ML Signal

SELL

Logo Agenus Inc.

AGEN

Agenus Inc.

HOLD

Current Price

$6.08

Market Cap

335.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PERI
AGEN
Founded
1999
1994
Country
Israel
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
346.5M
335.6M
IPO Year
2005
1999

Fundamental Metrics

Financial Performance
Metric
PERI
AGEN
Price
$8.72
$6.08
Analyst Decision
Buy
Strong Buy
Analyst Count
6
3
Target Price
$13.00
★ $26.33
AVG Volume (30 Days)
237.2K
★ 1.1M
Earning Date
11-11-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 100.00
EPS
N/A
★ 0.96
Revenue
N/A
★ $42,877,086.00
Revenue This Year
$5.75
$9.64
Revenue Next Year
$10.33
N/A
P/E Ratio
★ N/A
$6.96
Revenue Growth
N/A
★ 89.95
52 Week Low
$7.63
$2.71
52 Week High
$11.27
$10.19

Technical Indicators

Market Signals
Indicator
PERI
AGEN
Relative Strength Index (RSI) 48.09 33.94
Support Level $8.28 $2.96
Resistance Level $9.70 $8.64
Average True Range (ATR) 0.24 0.62
MACD 0.06 -0.29
Stochastic Oscillator 51.91 0.60

Price Performance

Historical Comparison
PERI
AGEN

About PERI Perion Network Ltd.

Perion Network Ltd is a technology company. It offers online advertising and search solutions to brands, agencies, and publishers through desktop, mobile, and social channels. It connects advertisers to consumers across digital advertising channels, including search advertising, social, display, video, digital audio, digital out of home (DOOH), and Connected TV (CTV) advertising. The company earns prime revenue from search advertising and display advertising services. It operates in the business segment of High Impact Advertising solutions. Geographically, the company generates a majority of its revenue from the United States and the rest from other regions.

About AGEN Agenus Inc.

Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.

Share on Social Networks: